BCMA targeted CAR T-cells / Shanghai Yake Biotech - LARVOL DELTA

CO-INFUSION OF CD19/BCMA-TARGETED CAR-T CELLS ERADICATES AUTOANTIBODY-PRODUCING CELLS IN SLE PATIENTS:A PHASE 1 CLINICAL TRIAL (EBMT 2025) - P1 | "In conclusion, the current study represents a significant step forward in the treatment of SLE, offering new hope for patients with refractory SLE. The identification of memory B cells and LLPCs as the main sources of autoantibodies and their role in the pathogenesis of SLE highlight the need for targeted therapies, such as CD19 and BCMA dual-targeting CAR-T cells. The comprehensive restoration of memory B cells and plasma cells post-CAR-T therapy and the clear shift towards a more protective immune response suggest a promising therapeutic approach for SLE."

CAR T-Cell Therapy • Clinical • P1 data • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

BCMA/CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ANTI-HLA​ ANTIBODY SENSITIZATION IN PATIENTS WITH ACUTE LEUKEMIA: A PILOT CLINICAL STUDY (EBMT 2025) - P1 | "Seven patients with acute leukemia [four with acute myeloid leukemia (AML) and three with B-cell acute lymphoblastic leukemia (B-ALL)] were enrolled, with one patient receiving BCMA-targeted CAR-T cells and six receiving CD19-targeted CAR-T cells (Table 1).Table 1... This pilot study demonstrates the effectiveness of CD19 and BCMA CAR-T cells in anti-HLA antibody desensitization in patients with AML or B-ALL. Clinical Trial Registry: The study protocol was approved by the First Affiliated Hospital, School of Medicine, Zhejiang University Institutional Review Board and registered in Chictr.org.cn (ChiCTR2100049920). ​Website: https://www.chictr.org.cn/showproj.html?proj=131722"

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology

BCMA/CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ANTI-HLA​ ANTIBODY SENSITIZATION IN PATIENTS WITH ACUTE LEUKEMIA: A PILOT CLINICAL STUDY (EBMT 2025) - P1 | "Seven patients with acute leukemia [four with acute myeloid leukemia (AML) and three with B-cell acute lymphoblastic leukemia (B-ALL)] were enrolled, with one patient receiving BCMA-targeted CAR-T cells and six receiving CD19-targeted CAR-T cells (Table 1).Table 1... This pilot study demonstrates the effectiveness of CD19 and BCMA CAR-T cells in anti-HLA antibody desensitization in patients with AML or B-ALL. Clinical Trial Registry: The study protocol was approved by the First Affiliated Hospital, School of Medicine, Zhejiang University Institutional Review Board and registered in Chictr.org.cn (ChiCTR2100049920). ​Website: https://www.chictr.org.cn/showproj.html?proj=131722"

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma. (PubMed, Front Immunol) - "Patients (n=105) with r/r MM treated with BCMA-targeted CAR-T cell therapy were included...TLS is a frequently observed CAR-T therapy complication and negatively influences clinical response and prognosis. Close monitoring for TLS should be implemented during CAR-T cell therapy, especially for those at high TLS risk."

CAR T-Cell Therapy • Journal • Hematological Malignancies • Multiple Myeloma • Oncology • CRP • IFNG • IL6

HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. (PubMed, Bone Marrow Transplant) - "Of 4 patients with HBV reactivation, 2 cases (50%) of severe hepatitis were noted and reported. Drops of serum IgG and elevation of alanine aminotransferase (ALT), alanine aminotransferase (AST), total bilirubin (TB) were observed in all four patients around the date of HBV reactivation."

CAR T-Cell Therapy • Journal • Hematological Malignancies • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Multiple Myeloma • Oncology

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Zhejiang University

CAR T-Cell Therapy • New P1 trial • Bone Marrow Transplantation • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Zhejiang University | Phase classification: P1 ➔ P2

CAR T-Cell Therapy • Phase classification • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Zhejiang University

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Zhejiang University

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma (clinicaltrials.gov) - P1; N=50; Not yet recruiting; Sponsor: Zhejiang University

Clinical • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology